^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    JAMA Otolaryngol Head Neck Surg
    Title:

    Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Select Targeted Therapies

    Excerpt:
    When treated with BEZ-235, H1047R-expressing cell lines showed increased sensitivity to inhibition compared with control, whereas those expressing E545K showed slightly increased sensitivity of unclear significance.
    DOI:
    10.1001/jamaoto.2015.0471
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

    Excerpt:
    As shown in Figure 3A, HNSCC cell lines containing endogenous PIK3CA(H1047R) mutations (CAL-33 and Detroit 562)(20) demonstrated increased sensitivity to PI3K pathway inhibition by the mTOR/PI3K inhibitor BEZ-235 compared to representative HNSCC cells with WT PIK3CA [SCC-9 and PE/CA-PJ34(clone C12)].
    DOI:
    10.1158/2159-8290.CD-13-0103